Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked in traditional channels.

Americans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk’s weight-loss and diabetes drugs but cannot always fill them because of supply issues and insurance hurdles, according to their doctors.